SABCS2020: Chemo-immune therapy as a first-line treatment of patients with metastatic triple-negative breast cancer

In this MEDtalk, Hope S. Rugo, MD, Professor of Medicine, University of California San Francisco, presents data from KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer.